Viral safety 2.0 - the power of next-generation sequencing
Snehit Satish Mhatre, Senior Scientific Director, Eurofins Biopharma Product Testing Denmark, SnehitSatish.Mhatre@bpt.eurofinseu.com
Traditional viral safety testing has long relied on in vivo and in vitro adventitious agent tests – methods that, while foundational, are limited by their narrow scope and lengthy turnaround times. As biopharmaceutical complexities increase, the industry has been transitioning toward viral safety, driven by the transformative power of Next-Generation Sequencing (NGS).
The challenge: risk and uncertainty
For clients, the limitations of legacy testing manifest as significant risks. Patients face the potential threat of “dark matter” viruses: emerging or cryptic contaminants that traditional assays fail to detect due to lack of specific primers or narrow host-cell susceptibility. For the client, these gaps translate into regulatory uncertainty and operational bottlenecks. A contamination event detected late in the manufacturing cycle can lead to catastrophic facility shutdowns, supply chain disruptions, and most importantly, compromised patient safety. Furthermore, the 28-day duration of traditional cell-based assays delays the delivery of life-saving therapies, particularly in the fast-paced field of Advanced Therapy Medicinal Products (ATMPs).
The solution: a client-centric NGS strategy
As a service provider, making NGS “client-centric” means evolving beyond mere data generation to provide actionable intelligence. By leveraging Metagenomic NGS (mNGS), Eurofins BPT offers a “catch-all” diagnostic tool that identifies known and unknown sequences simultaneously. To address client pain points, our approach focuses on:
- Accelerated timelines: reducing testing cycles from weeks to days, allowing for faster batch release.
- Bioinformatic clarity: translating complex genomic data into simplified, risk-based reports that ease the burden of regulatory filings.
- Mitigation of false positives: implementing robust bioinformatic pipelines to distinguish between environmental noise and genuine biological threats.
Ultimately, NGS is not just a technological upgrade; it is a commitment to a higher standard of care. By integrating NGS, Eurofins BPT provides clients with a proactive safety net, ensuring that the path from bench to bedside is swifter, more transparent, and uncompromisingly secure. For more information, visit: Next-Generation Sequencing(NGS) - Eurofins Denmark